文献速递前列腺癌

高危前列腺癌放疗转诊患者PSMA PET/CT分期迁移:THUNDER 2/3期试验首年结果

Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial.
PubMed 文献 · Eur Urol Oncol · 2025-09-25

THUNDER 2/3期试验首年纳入142例高危前列腺癌患者,在筛查前16周内同时完成常规影像(CT、骨显像)与PSMA PET/CT,按TNM与miTNM(PROMISE v2)标准比较分期。PSMA PET/CT导致43例分期迁移,其中42例(30%)上调、1例(1%)下调;上调至miN1-2者32例(23%),上调至miM1a-c者19例(13%)。作者认为约三分之一拟行根治性放疗的高危患者被上调分期,支持用PSMA PET/CT分期,尤其在多项高危特征患者中。

要点

  • 高危前列腺癌放疗转诊患者中30%经PSMA PET/CT上调分期
  • 上调至miN1-2为23%,上调至miM1a-c为13%
  • 符合STAMPEDE M0高危标准者上调比例达37%

核心结论

  • 约三分之一拟行根治性放疗的高危前列腺癌患者在PSMA PET/CT上被上调分期。
  • 该结果支持将PSMA PET/CT用于分期,尤其是具有多项高危特征的患者,并提示需相应调整治疗。

研究设计与样本

  • 2/3期THUNDER试验(NCT06282588)首年纳入分析,为描述性统计研究。
  • 按TNM分类与分子影像miTNM分类(PROMISE v2标准)评估分期迁移。

主要发现

  • PSMA PET/CT导致43例分期迁移,其中42例(30%)上调、1例(1%)下调。
  • 上调至miN1-2疾病32例(23%),上调至miM1a-c疾病19例(13%)。
  • 上调概率随高危特征数量增加而升高。
  • 符合STAMPEDE M0高危标准亚组(n=73)中27例(37%)上调,其中14例(19%)上调至miM1a-c。

关键数值与推荐

  • proPSMA试验中PSMA PET/CT上调分期比例为14%,本研究假设放疗转诊人群更高。
  • 分期迁移判定依据TNM与miTNM(PROMISE v2)分类。

临床怎么用

  • 对拟行根治性放疗的高危前列腺癌患者,可考虑以PSMA PET/CT进行分期。
  • 高危特征较多者上调概率更高,应据此评估并考虑治疗调整。
  • 治疗适配策略将在THUNDER试验中进一步研究。

局限性

  • 影像检查过程缺乏中心化复核。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: In high-risk prostate cancer, the proPSMA trial showed upstaging with prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) in 14% of patients. We hypothesised that the probability of stage migration in a patient population referred for curative-intent radiotherapy would be higher. Here we report stage migration results according to PSMA PET/CT in the first year of inclusion in the phase 2/3 THUNDER trial (NCT06282588). METHODS: Patients with high-risk prostate cancer screened between December 2023 and December 2024 in the THUNDER trial with both conventional imaging (CT, bone scintigraphy) and PSMA PET/CT within 16 weeks before screening were included (n = 142). Stage migration according to the TNM classification versus the molecular imaging (miTNM) classification (PROMISE v2 criteria) was assessed using descriptive statistics. KEY FINDINGS AND LIMITATIONS: PSMA PET/CT led to stage migration in 43 patients, of whom 42 (30%) were upstaged and one (1%) was downstaged. Upstaging to miN1-2 disease occurred in 32 patients (23%), and to miM1a-c disease in 19 patients (13%). The probability of upstaging increased with the number of high-risk features. In the subgroup meeting the STAMPEDE M0 high-risk criteria (n = 73), PSMA PET/CT upstaged 27 patients (37%), including upstaging to miM1a-c disease in 14 (19%). Limitations include the absence of central review of the imaging procedures. CONCLUSIONS AND CLINICAL IMPLICATIONS: One-third of patients with high-risk prostate cancer referred for curative-intent radiotherapy were upstaged on PSMA PET/CT. This finding supports the use of PSMA PET/CT for staging, especially in patients with multiple high-risk features, and suggests a need for treatment adaptations accordingly, which will be further investigated in the THUNDER trial.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Kleiburg F, Dirix P, Fonteyne V, et al. Stage Migration on Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Comparison to Conventional Imaging in Patients with High-risk Prostate Cancer Referred for Radiation Therapy: Results from the Phase 2/3 THUNDER Trial. Eur Urol Oncol. 2025. PMID: 40998687. doi:10.1016/j.euo.2025.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。